Phase I Study of Olaparib and Temozolomide in patients with recurrent andor metastatic Ewing sarcoma An Interim Update Edwin Choy Gregory Cote James Butrynski David Harmon Suzanne George Andrew Wagner Jeffrey Morgan David DAdamo George Demetri ID: 764357
Download Presentation The PPT/PDF document "Phase I Study of Olaparib and Temozolomi..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Phase I Study of Olaparib and Temozolomide, in patients with recurrent and/or metastatic Ewing sarcoma : An Interim Update Edwin Choy, Gregory Cote, James Butrynski, David Harmon, Suzanne George, Andrew Wagner, Jeffrey Morgan, David D’Adamo, George Demetri
Olaparib/EWS-FlI1 interaction is one of the strongest associations among 639 cell lines and 130 drugs screened
Olaparib prevents EWS-FLI1-positive xenograft growth and metastasis.
Single Agent Olaparib is Not Effective in Ewing Sarcoma Choy et al. BMC Cancer. In Press
Single Agent Olaparib is Not Effective in Ewing Sarcoma Choy et al. BMC Cancer. In Press
Olaparib synergizes with TMZ in EWS-FLI1-positive xenograft mice
Objectives of this Phase 1 trial
Study Design: Phase I 3+3 dose escalation study of olaparib and temozolomide in patients with recurrent and/or metastatic Ewing’ s sarcoma. Treatment regimen: Olaparib is administered orally with temozolomide on an outpatient basis, given for 7 days every 21 days. Imaging:CT/MRI prior to starting study drug, after 6 and 12 weeks from starting study drug, and every 9 weeks thereafter. Additional scans may be performed as clinically indicated. Subjects will continue to be followed until disease progression or death.
Inclusion Criteria: Histologically-confirmed Ewing ’s sarcoma. Measurable disease on cross sectional imaging of at least 1cm ECOG performance status 0-2 Life expectancy >3 months Age ≥ 18 years.Patients must have received at least one line of chemotherapy, including adjuvant therapy , for the initial treatment of Ewing ’ s sarcoma. There will be no limits on number of prior regimens using chemotherapy or investigational agents. Allowed for prior treatment with temozolomide
Dose Levels
Attributable AEs
Best Response by RECIST 1.1 * Received prior TMD * * * * * * * *
Dose Level DLTs 1 0/3 2 0/3 3 0/3 4 0/3 5 2/2 # of DLTs per Dose Level
Conclusions We designed and conducted a phase I clinical trial to administer olaparib and temozolomide in patients with Ewing sarcoma progressing after prior chemotherapy 5 dose levels were tested minor responses were seen in 6 of 14 evaluable patients MTD was surpassed at dose level 5 Dose expansion study will be performed using olaparib at 200 mg BID and temozolomide at 75 mg/m2 QD.
AcknowledgmentsMentorship George Demetri, DFCIDaniel Haber, MGHJose Baselga , MGHJane Robertson, Astra ZenecaClinical Trials Unit at DFCI and MGH Coauthors Kristina Goodman Barbara Anderson David Wells Eleanor Saffian Basyl Stuyvesant Melissa Hohos Mark Morley Julie Field Sarah Solomon Funds Ludwig Center at Dana-Farber / Harvard Cancer Center Jennifer Hunter Yates Sarcoma Foundation Brian MacIsaac Sarcoma Fund